Latest Breaking News On - ஜப்பானிய கட்டம் - Page 2 : comparemela.com

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad . Fortress Biotech, Inc.May 10, 2021 GMT Agreement signed with Fuji Yakuhin to develop Dotinurad, a potential best-in-class urate transporter (URAT1) inhibitor for gout and potentially other hyperuricemic indications including chronic kidney disease and heart failure Dotinurad (URECE® tablet) was approved in Japan in 2020 as a once-daily oral therapy for gout and hyperuricemia Dotinurad was efficacious and well-tolerated in more than 500 Japanese patients treated for up to 58 weeks in Phase 3 clinical trials NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or the “Company”), an innovative biopharmaceutical company, today announced that it has entered into an exclusive licensing agreement with Fuji Yakuhin Co. Ltd. (“Fuji”) to develop Dot

United statesUnited kingdomJaclyn jaffeLindsaya rosenwaldTony plohorosCompany contactsLifesci advisorsJude children research hospitalTechnology fastAlexion pharmaceuticals incEuropean unionSecurities exchangeFuji yakuhin coFortress biotech incFred hutchinson cancer research centerFuji yakuhin